Halozyme Financial Statements From 2010 to 2025

HALO Stock  USD 62.54  0.41  0.65%   
Halozyme Therapeutics financial statements provide useful quarterly and yearly information to potential Halozyme Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Halozyme Therapeutics financial statements helps investors assess Halozyme Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Halozyme Therapeutics' valuation are summarized below:
Gross Profit
776.9 M
Profit Margin
0.4374
Market Capitalization
7.8 B
Enterprise Value Revenue
8.4466
Revenue
B
We have found one hundred twenty available fundamental trends for Halozyme Therapeutics, which can be analyzed and compared to other ratios and to its competitors. Self-guided Investors are advised to confirm Halozyme Therapeutics' regular fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 18th of March 2025, Market Cap is likely to grow to about 2 B. Also, Enterprise Value is likely to grow to about 2 B

Halozyme Therapeutics Total Revenue

1.07 Billion

Check Halozyme Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Halozyme Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 85.4 M, Interest Expense of 19 M or Selling General Administrative of 162.1 M, as well as many indicators such as Price To Sales Ratio of 5.67, Dividend Yield of 0.0 or PTB Ratio of 15.83. Halozyme financial statements analysis is a perfect complement when working with Halozyme Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Halozyme Therapeutics Correlation against competitors.
To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.

Halozyme Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets2.2 B2.1 B745.4 M
Slightly volatile
Other Current Liabilities135.3 M128.9 M46.7 M
Slightly volatile
Total Current Liabilities71.1 M139.1 M97.6 M
Slightly volatile
Cash83.6 M115.8 M94.8 M
Slightly volatile
Cash And Short Term Investments625.9 M596.1 M309.2 M
Slightly volatile
Common Stock Total Equity104.5 K155.2 K121.5 K
Slightly volatile
Common Stock Shares Outstanding106.3 M129.4 M120.7 M
Slightly volatile
Liabilities And Stockholders Equity2.2 B2.1 B745.4 M
Slightly volatile
Other Stockholder Equity2.6 M2.8 M357.7 M
Pretty Stable
Total Liabilities1.8 B1.7 B621.2 M
Slightly volatile
Total Current Assets1.1 B1.1 B472.1 M
Slightly volatile
Common Stock107.2 K123 K119.2 K
Slightly volatile
Short and Long Term Debt Total1.6 B1.5 B532.9 M
Slightly volatile
Accounts Payable5.4 M10.2 M5.7 M
Slightly volatile
Property Plant And Equipment Net78.8 M75 M22.9 M
Slightly volatile
Non Current Assets TotalB978.1 M273.4 M
Slightly volatile
Non Currrent Assets Other84.6 M80.6 M17.3 M
Slightly volatile
Inventory149 M141.9 M45.6 M
Slightly volatile
Other Current Assets22.6 M39 M27.7 M
Slightly volatile
Property Plant And Equipment Gross105.5 M100.5 M29.1 M
Slightly volatile
Property Plant Equipment91.3 M86.9 M24.4 M
Slightly volatile
Net Receivables323.9 M308.5 M92.7 M
Slightly volatile
Other Liabilities26.6 M16 M26.9 M
Slightly volatile
Non Current Liabilities Total1.6 B1.6 B520.1 M
Slightly volatile
Capital Surpluse29.9 M31.5 M374.7 M
Slightly volatile
Long Term Debt Total1.8 B1.7 B565.2 M
Slightly volatile
Capital Lease Obligations1.2 M1.3 M1.4 M
Slightly volatile
Non Current Liabilities Other57.5 M54.8 M13.4 M
Slightly volatile
Short and Long Term Debt14.6 M15.3 M63.8 M
Very volatile
Net Invested Capital1.1 B1.9 B750.6 M
Slightly volatile
Net Working Capital583.9 M946.2 M467.7 M
Slightly volatile
Capital Stock107.4 K123 K138 K
Slightly volatile

Halozyme Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative162.1 M154.3 M68.4 M
Slightly volatile
Selling And Marketing Expenses588315411
Slightly volatile
Total Revenue1.1 BB341 M
Slightly volatile
Gross Profit898.7 M855.9 M280.8 M
Slightly volatile
Other Operating Expenses487 M463.8 M230.3 M
Slightly volatile
Cost Of Revenue167.4 M159.4 M60.2 M
Slightly volatile
Total Operating Expenses319.7 M304.4 M170.1 M
Slightly volatile
Research Development77.6 M79 M85.4 M
Very volatile
Interest IncomeM4.2 M6.8 M
Pretty Stable
Reconciled Depreciation85.4 M81.3 M20.7 M
Slightly volatile

Halozyme Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow83.8 M115.8 M95 M
Slightly volatile
Begin Period Cash Flow81.9 M118.4 M92.9 M
Slightly volatile
Depreciation85.4 M81.3 M20.3 M
Slightly volatile
Stock Based Compensation22.1 M43.4 M22.2 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio5.675.972125.7704
Slightly volatile
Days Sales Outstanding167111156
Slightly volatile
Average PayablesM2.4 M2.7 M
Very volatile
Stock Based Compensation To Revenue0.04060.04270.1381
Slightly volatile
Capex To Depreciation0.120.13150.9137
Slightly volatile
EV To Sales6.977.341126.308
Slightly volatile
Inventory Turnover1.311.12381.6609
Very volatile
Days Of Inventory On Hand574325479
Slightly volatile
Payables Turnover16.3315.554410.7206
Slightly volatile
Sales General And Administrative To Revenue0.440.460.4987
Slightly volatile
Average Inventory1.5 M1.5 M1.4 M
Slightly volatile
Research And Ddevelopement To Revenue0.0740.07795.6437
Slightly volatile
Capex To Revenue0.010.01050.1887
Slightly volatile
Cash Per Share4.934.69992.3294
Slightly volatile
Days Payables Outstanding22.2923.466791
Slightly volatile
Income Quality0.691.07881.0105
Very volatile
Current Ratio6.727.80265.3442
Pretty Stable
Receivables Turnover6.413.29166.3717
Slightly volatile
Graham Number15.7915.03356.1699
Slightly volatile
Capex Per Share0.08860.08430.0328
Slightly volatile
Average Receivables11.7 M11.2 M10.9 M
Slightly volatile
Revenue Per Share8.418.00562.6029
Slightly volatile
Interest Debt Per Share12.6212.01554.1256
Slightly volatile
Debt To Assets0.90.72970.7904
Pretty Stable
Operating Cycle733436634
Slightly volatile
Days Of Payables Outstanding22.2923.466791
Slightly volatile
Ebt Per Ebit0.961.010363.2341
Slightly volatile
Long Term Debt To Capitalization0.590.80540.6928
Pretty Stable
Total Debt To Capitalization0.620.80540.7492
Very volatile
Quick Ratio6.476.78275.0062
Very volatile
Net Income Per E B T0.740.79710.9297
Pretty Stable
Cash Ratio0.790.83291.9181
Slightly volatile
Days Of Inventory Outstanding574325479
Slightly volatile
Days Of Sales Outstanding167111156
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.930.97771.0129
Slightly volatile
Fixed Asset Turnover16.4213.531325.463
Very volatile
Debt Ratio0.90.72970.7904
Pretty Stable
Price Sales Ratio5.675.972125.7704
Slightly volatile
Asset Turnover0.340.4920.515
Slightly volatile
Gross Profit Margin0.610.8430.796
Very volatile

Halozyme Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market CapB1.9 B1.6 B
Slightly volatile
Enterprise ValueBB1.7 B
Slightly volatile

Halozyme Fundamental Market Drivers

Forward Price Earnings13.4409
Cash And Short Term Investments596.1 M

Halozyme Upcoming Events

20th of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Halozyme Therapeutics Financial Statements

Halozyme Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Halozyme Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-29 M-27.5 M
Total RevenueB1.1 B
Cost Of Revenue159.4 M167.4 M
Stock Based Compensation To Revenue 0.04  0.04 
Sales General And Administrative To Revenue 0.46  0.44 
Research And Ddevelopement To Revenue 0.08  0.07 
Capex To Revenue 0.01  0.01 
Revenue Per Share 8.01  8.41 
Ebit Per Revenue 0.54  0.57 

Pair Trading with Halozyme Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Halozyme Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Halozyme Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Halozyme Stock

  0.62DMAC DiaMedica TherapeuticsPairCorr
  0.83VALN Valneva SE ADRPairCorr

Moving against Halozyme Stock

  0.93VINC Vincerx PharmaPairCorr
  0.9VERA Vera TherapeuticsPairCorr
  0.9VKTX Viking TherapeuticsPairCorr
  0.79DSGN Design TherapeuticsPairCorr
  0.75VANI Vivani Medical Earnings Call This WeekPairCorr
The ability to find closely correlated positions to Halozyme Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Halozyme Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Halozyme Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Halozyme Therapeutics to buy it.
The correlation of Halozyme Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Halozyme Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Halozyme Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Halozyme Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Halozyme Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Halozyme Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Halozyme Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Halozyme Therapeutics Stock:
Check out the analysis of Halozyme Therapeutics Correlation against competitors.
To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.623
Earnings Share
3.43
Revenue Per Share
8.006
Quarterly Revenue Growth
0.295
Return On Assets
0.1816
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.